Vanda rejects Future Pak and Cycle Pharma`s takeover offers
Cycle Pharmaceuticals has proposed to acquire all issued and outstanding shares of Vanda Pharmaceuticals for $8 per share in cash, valuing the deal at $466m.
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
New tiopronin delayed-release tablets launch with patient support for the treatment of cystinuria in the US
New US product, ORMALVI™ (dichlorphenamide) tablets, launches for Primary Periodic Paralysis (PPP) treatment
BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (Cycle) has today announced the launch of TASCENSO ODT, its first product to treat MS patients in the US. The launch ensures MS patients in the US currently benefitting from Gilenya, or generic fingolimod, can access appropriate patient support services alongside the bioequivalent, non-generic, TASCENSO ODT. Gilenya patient support services are scheduled to be withdrawn on March 31st 2023.1,2,3
Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT® (fingolimod)
BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle) is pleased to announce the launch of SAJAZIR™ (icatibant) Injection, a new treatment option for patients affected by Hereditary Angioedema (HAE) approved by the US Food and Drug Administration (FDA).
BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle) is pleased to announce the launch of its Boston-based support platform for rare disease patients, Cycle Vita™.
RadioMedix’s Detectnet (copper Cu 64 dotatate injection) has been approved for the detection of somatostatin receptor‒positive neuroendocrine tumors (NETs) in adult patients during imaging with positron emission tomography.